These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 20944133)

  • 21. Increased expression of the RIalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer.
    McDaid HM; Cairns MT; Atkinson RJ; McAleer S; Harkin DP; Gilmore P; Johnston PG
    Br J Cancer; 1999 Feb; 79(5-6):933-9. PubMed ID: 10070893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines.
    Duan Z; Lamendola DE; Duan Y; Yusuf RZ; Seiden MV
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):277-85. PubMed ID: 15565326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis.
    Le XF; Hittelman WN; Liu J; McWatters A; Li C; Mills GB; Bast RC
    Oncogene; 2003 Jan; 22(4):484-97. PubMed ID: 12555062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
    Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
    Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer.
    Sabine VS; Sims AH; Macaskill EJ; Renshaw L; Thomas JS; Dixon JM; Bartlett JM
    Breast Cancer Res Treat; 2010 Jul; 122(2):419-28. PubMed ID: 20480226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
    Hartman ML; Esposito JM; Yeap BY; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2010 May; 139(5):1233-40. PubMed ID: 19853261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Up-regulation of Foxp3 inhibits cell proliferation, migration and invasion in epithelial ovarian cancer.
    Zhang HY; Sun H
    Cancer Lett; 2010 Jan; 287(1):91-7. PubMed ID: 19628330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells.
    Ji J; Zheng PS
    Gynecol Oncol; 2010 Apr; 117(1):103-8. PubMed ID: 20102778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.
    L'Espérance S; Popa I; Bachvarova M; Plante M; Patten N; Wu L; Têtu B; Bachvarov D
    Int J Oncol; 2006 Jul; 29(1):5-24. PubMed ID: 16773180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy.
    Zhang HY; Zhang PN; Sun H
    Eur J Obstet Gynecol Reprod Biol; 2009 Sep; 146(1):81-6. PubMed ID: 19540648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro.
    Rogers-Broadway KR; Chudasama D; Pados G; Tsolakidis D; Goumenou A; Hall M; Karteris E
    Int J Oncol; 2016 Jul; 49(1):133-43. PubMed ID: 27211906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.
    Nagaraja AK; Creighton CJ; Yu Z; Zhu H; Gunaratne PH; Reid JG; Olokpa E; Itamochi H; Ueno NT; Hawkins SM; Anderson ML; Matzuk MM
    Mol Endocrinol; 2010 Feb; 24(2):447-63. PubMed ID: 20081105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry.
    Rogers-Broadway KR; Kumar J; Sisu C; Wander G; Mazey E; Jeyaneethi J; Pados G; Tsolakidis D; Klonos E; Grunt T; Hall M; Chatterjee J; Karteris E
    Int J Mol Med; 2019 Jan; 43(1):47-56. PubMed ID: 30387804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Demonstration of differential gene expression between sensitive and resistant ovarian tumor cells by fluorescence differential display-PCR analysis.
    Li L; Luan Y; Li X; Tang B; Zhang W; Li D; Zhao J; Wang G; Ding H; Reed E; Li QQ
    Oncol Rep; 2005 May; 13(5):793-9. PubMed ID: 15809740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT.
    Yellepeddi VK; Kumar A; Maher DM; Chauhan SC; Vangara KK; Palakurthi S
    Anticancer Res; 2011 Mar; 31(3):897-906. PubMed ID: 21498711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hcrcn81 is upregulated by rapamycin treatment in human colorectal adenocarcinoma cells.
    Wen X; Dong L; Zhu J; Chen Y
    Mol Med Rep; 2013 Apr; 7(4):1257-60. PubMed ID: 23404111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of communication in ovarian cancer.
    Toler CR; Taylor DD; Gercel-Taylor C
    Am J Obstet Gynecol; 2006 May; 194(5):e27-31. PubMed ID: 16647893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reprogramming of the microRNA transcriptome mediates resistance to rapamycin.
    Totary-Jain H; Sanoudou D; Ben-Dov IZ; Dautriche CN; Guarnieri P; Marx SO; Tuschl T; Marks AR
    J Biol Chem; 2013 Mar; 288(9):6034-44. PubMed ID: 23300087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alteration in the mRNA expression profile of the autophagy-related mTOR pathway in schizophrenia patients treated with olanzapine.
    Cui F; Gu S; Gu Y; Yin J; Fang C; Liu L
    BMC Psychiatry; 2021 Aug; 21(1):388. PubMed ID: 34348681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of basal signaling heterogeneity can distinguish cellular populations with different drug sensitivities.
    Singh DK; Ku CJ; Wichaidit C; Steininger RJ; Wu LF; Altschuler SJ
    Mol Syst Biol; 2010 May; 6():369. PubMed ID: 20461076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.